The Custom Supplement Boom Has a Testing Problem Nobody's Talking About

The company that packs your “custom” daily supplement pouch — the one your health quiz results generated — is almost certainly managing more active SKUs per square foot of production space than a conventional supplement manufacturer would consider workable. That’s not a criticism. It’s a structural reality of personalized nutrition, and it creates a testing challenge that the industry hasn’t fully reckoned with yet.

The global personalized nutrition market is on track to surpass $37 billion by 2030, according to projections from Grand View Research — up from roughly $14 billion in 2023. That’s approximately a 14% compound annual growth rate, and it’s attracting serious capital. Bayer acquired Care/of. Nestlé Health Science has been quietly building out its personalized nutrition infrastructure for years. Direct-to-consumer brands are proliferating faster than the quality frameworks needed to support them.

What’s not keeping up? The testing infrastructure those brands actually need.

Why Standard GMP Testing Assumptions Don’t Transfer to Custom Blends

Here’s a foundational reality of supplement manufacturing: FDA’s 21 CFR Part 111 — the GMP regulations governing dietary supplement quality — was written with conventional batch manufacturing in mind. A batch of 50,000 capsules allows you to pull statistically meaningful samples, run finished product testing, and have high confidence that your results represent the full lot. The sampling logic holds.

Drop that batch size to 500 units — or even 50 individual custom pouches, which is what some personalized brands work with per unique SKU per production run — and the sampling math changes in ways that matter. A 1% sample of 50,000 is 500 units, which provides plenty of material for identity, potency, and microbial testing. A 1% sample of 50 pouches is half a pouch. The regulations don’t disappear because your batch is small, but the testing paradigm absolutely has to shift.

We see this play out regularly when brands come to us after launching. They’ve been applying the same finished product testing cadence they’d use for a mass-market product — quarterly composite tests, annual microbial sweeps — without stopping to ask whether that schedule reflects actual risk for a product line that changes formulation every time a customer updates their health profile. The honest answer, in most cases, is that it doesn’t.

The Ingredient Identity Problem Is Bigger Than Most Brands Anticipate

One of the clearest differences between a well-run personalized supplement program and a liability in waiting is ingredient-level identity testing. And it’s where a lot of brands take shortcuts they later regret.

With a conventional supplement, you establish identity on your raw materials through a supplier qualification program — HPTLC, NIR spectroscopy, or DNA barcoding for botanicals, depending on complexity — and you can reasonably rely on that qualified supplier relationship for ongoing production. The raw material arrives, you verify it against your approved specification, and your finished product identity is defensible under FDA’s Part 111 framework.

Custom blends complicate this considerably. You may be working with 40, 60, or more than 100 active ingredients across potentially thousands of possible formulation combinations. Identity risk multiplies at every step. A cross-contamination event that would be a contained, single-product recall for a conventional brand becomes a much harder problem when the same production line touches 150 different SKUs in a week — because now you have to ask which of those SKUs might have been affected.

USP <563>, which covers botanical identity verification, isn’t new. But its practical application for personalized brands is still catching up to the market reality. When we work with companies in this space, we typically recommend component-level identity testing on incoming raw material lots — not just at initial supplier qualification, but on every shipment. That’s not always the answer brands want to hear when they’re watching margins. But the cost of a downstream identity failure at this SKU count is considerably higher than the testing that would have prevented it.

Potency Variability and the Precision Problem

Potency testing for personalized supplements deserves specific attention because the failure mode here is subtle — and it tends to show up in customer behavior before it surfaces in regulatory data.

Industry norms, and most finished product specifications, allow for ±10–20% variance from label claim depending on the ingredient and applicable standard. For a shelf-stable vitamin C tablet sold at retail, that tolerance range is entirely reasonable. Ingredients degrade, moisture intrudes, and compression affects bioavailability — a realistic spec accounts for all of that.

But for a personalized product where the customer has been explicitly told their daily pack contains exactly 500 mg of magnesium glycinate and 40 mg of CoQ10 based on a personalized health assessment, that variance carries different weight. These customers are paying a meaningful premium for customization and precision. A 15% underage on a clinically meaningful ingredient isn’t just a labeling compliance issue — it’s a product integrity failure that will appear in churn data and one-star reviews long before it shows up in an FDA inspection finding.

The practical implication: personalized brands need tighter finished product specs and more frequent potency verification than a conventional brand would typically run. We generally recommend testing every formulation variant at launch, then at defined stability timepoints — not just the highest-volume configurations. The argument that it’s not cost-effective to test every combination is understandable, but it doesn’t protect the brand when a specific configuration fails in the field.

Where FDA Regulations Land — and Where They Don’t

The FDA’s position on personalized supplements is worth stating plainly: there is no separate regulatory framework for this business model. You are manufacturing dietary supplements. 21 CFR Part 111 applies in full. The fact that your product was generated by an algorithm, packaged in a custom daily sachet, or sold exclusively through a subscription model creates zero carve-out from GMP compliance obligations.

Some brands have been operating under a mistaken belief that small batch sizes or DTC distribution reduce regulatory exposure. They don’t. FDA warning letters in the broader supplement space have been consistent on this point — the agency isn’t sympathetic to the argument that a sales model is novel when the underlying product risk is conventional.

What remains genuinely unsettled is how FDA will eventually address personalization schemes that approach individualized compounding — a regulatory category operating under a different framework within the FD&C Act. Brands formulating truly individualized products at the direction of a licensed practitioner are working in territory where FDA hasn’t issued definitive guidance. That ambiguity creates flexibility in the short term and regulatory uncertainty in the longer term.

For now, the safest position is to treat every SKU in your lineup — however it was generated — as a full dietary supplement subject to all applicable GMP requirements. Build your documentation to that standard. You won’t regret the rigor, and you’ll absolutely regret not having it.

Building a Testing Framework That Actually Fits the Model

What does a workable quality program look like for a personalized supplement brand? Based on the programs we’ve developed with clients in this space, a few principles consistently hold:

Test at the raw material level first. Establish identity, purity, and microbiological specifications for every ingredient in your formulation library before it enters any blend. This is your highest-leverage testing investment because it protects every product that ingredient could ever appear in — which, in a personalized model, could be thousands of combinations.

Develop finished product specifications for formulation families, not individual SKUs. With potentially thousands of unique combinations, independently validating each one isn’t realistic. Group by ingredient type, dose range, and delivery form, and validate representative formulations from each family. Document your scientific rationale for the grouping — FDA will expect to see it.

Run a real stability program. Personalized brands often defer stability testing because their product lines feel too dynamic to justify the investment. That reasoning doesn’t survive scrutiny. Identify your most complex and highest-risk formulation families, run ICH Q1A-aligned accelerated and real-time studies, and establish defensible expiration dates. A 24-month shelf life claim requires either 24 months of real-time data or a validated accelerated model built on appropriate degradation kinetics.

Document your supply chain at depth. Personalized brands typically source more individual ingredients than conventional brands, which means more supplier relationships, more certificates of analysis to review, and more substitution risk when a supplier quietly changes a raw material specification. Your supplier qualification records need to reflect that complexity.

We run incoming raw material testing — including HPTLC-based botanical identity panels and ICP-MS heavy metals screening — for several personalized supplement brands operating out of California. The brands that invest upstream in raw material testing consistently have fewer downstream problems. That pattern holds across every program we’ve run.

Getting Ahead of the Quality Gap

The personalized supplement space is one of the more interesting corners of the industry to work in right now, and the brands that build genuine quality infrastructure early will have a durable competitive advantage. Consumers who discover a brand they trust at the level of product quality tend to stay — and in a subscription business, retention is the entire economic model.

The brands cutting testing corners in this category are building on a foundation that market conditions, consumer complaints, and eventual regulatory attention will expose. Working with an ISO 17025 accredited testing partner who understands the specific demands of a personalized model — and who can help you design a program proportionate to your actual risk profile — is an investment in the brand’s future, not just a compliance checkbox.

If your formulation library has grown faster than your testing program, that’s not unusual. We see it constantly. But the time to close that gap is before a complaint investigation or a regulatory inspection, not during one.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• FDA Regulatory Strategy and GMP Compliance for Supplement Brands — Aurora TIC helps manufacturers navigate 21 CFR Part 111, audit readiness, and FDA enforcement risk before problems arise.
• Raw Material Identity and Purity Testing for Supplement Ingredients — Ayah Labs provides B2B raw material testing, COA verification, and supplier qualification support for ingredient suppliers worldwide.